Institutional Infrastructure
for Venture Capital
Syndication & Co-Investment

Spain-based spacetech startup Sateliot has launched a €100 million Series C funding round to accelerate the deployment of its 5G satellite constellation, signaling a major push toward building Europe’s sovereign space-based connectivity infrastructure.The round, primarily structured as equity with a potential debt component, is expected to close by summer and could include up to 50% public co-financing through institutional support. This reflects increasing alignment between private capital and government-backed initiatives aimed at strengthening Europe’s digital and technological independence.Founded to bridge the connectivity gap between terrestrial and satellite networks, Sateliot is developing a constellation of 16 low Earth orbit satellites capable of delivering standard 5G connectivity directly to IoT devices. Unlike traditional satellite systems, the company’s approach integrates seamlessly with existing telecom infrastructure, enabling global coverage without requiring specialized hardware.The newly raised capital will be used to accelerate the deployment of its satellite network and scale commercial operations globally. The company aims to provide reliable connectivity in remote and underserved regions, supporting use cases across logistics, agriculture, environmental monitoring, and defense.Sateliot’s expansion comes at a time when Europe is increasingly prioritizing space-based infrastructure to reduce reliance on non-European providers and strengthen strategic autonomy. As satellite connectivity becomes a critical layer of global digital infrastructure, companies like Sateliot are emerging as key players in the race to build next-generation communication networks.With this Series C round, Sateliot is positioning itself at the forefront of the rapidly evolving spacetech ecosystem, aiming to establish a scalable and interoperable 5G satellite network that bridges terrestrial and non-terrestrial communications worldwide.

India’s venture debt ecosystem crossed $1.3 billion in deployments in 2025, highlighting the growing importance of non-dilutive capital as startups increasingly diversify their funding strategies amid a shifting investment landscape.Despite a slowdown in overall deal activity, venture debt continued to gain traction as a preferred financing route, reflecting a broader shift in how startups structure capital. The rise of venture debt signals a move away from equity-heavy funding models toward more balanced and capital-efficient approaches.The fintech sector emerged as the largest contributor, accounting for nearly $600 million—around 46% of total venture debt deployment—underscoring its continued dominance within India’s startup ecosystem. Consumer-focused startups followed, while sectors such as cleantech, energy, and agritech also saw increasing participation, indicating diversification across industries.The data also highlights a structural evolution in India’s private debt market, where venture debt has grown from a niche instrument to a mainstream funding tool. Over the past few years, its share in overall startup financing has increased significantly, with founders increasingly using debt to extend runway, manage working capital, and avoid equity dilution.At the same time, growth credit is emerging as a complementary layer of financing, targeting more mature startups with larger capital requirements. In 2025, growth credit deployments reached approximately $1.68 billion, reflecting the development of a more sophisticated and layered funding ecosystem.This evolution points toward a maturing startup ecosystem in India, where structured capital stacks-combining equity, venture debt, and growth credit-are becoming increasingly common. As market conditions remain dynamic, venture debt is expected to play a critical role in enabling sustainable and capital-efficient growth for startups across sectors.

UK-based healthtech startup Neupulse has raised £3 million in new funding, signaling strong investor confidence in next-generation neurotherapeutic solutions aimed at addressing unmet needs in brain health.The funding round was led by Eos Advisory and the Midlands Engine Investment Fund II, managed by Mercia Ventures, with participation from both new and existing investors, highlighting continued backing from institutional healthcare-focused capital.Neupulse is developing a non-drug wearable device designed to help manage symptoms of Tourette Syndrome, a condition that currently relies heavily on medication and behavioral therapy. The company’s technology delivers controlled electrical stimulation to the wrist, aiming to regulate brain activity associated with involuntary tics and provide patients with a more accessible and user-friendly treatment option.The newly raised capital will be used to scale sales, advance product development, and support regulatory milestones as the company moves toward commercial launch, expected in 2026. The funding will also enable further clinical validation and early-stage commercialization efforts to ensure the technology reaches patients who need it most.As demand grows for non-invasive and clinically validated treatments in neurological care, Neupulse is positioning itself within the emerging neurotech and digital therapeutics space. The company’s approach reflects a broader shift toward personalized, device-based interventions that can complement or replace traditional pharmaceutical treatments.With this funding, Neupulse aims to transition from development to market deployment, positioning itself as a key innovator in the neurotherapeutics landscape and contributing to the evolution of modern brain health treatment solutions.

San Francisco-based AI startup Luminai has raised $38 million in a Series B funding round, highlighting growing investor confidence in AI-driven enterprise automation for complex healthcare operations.The round was led by Peak XV Partners, with participation from Define Ventures, General Catalyst, and Y Combinator, reflecting strong backing from global investors focused on scaling applied AI solutions in high-impact industries.Founded in 2020, Luminai develops AI-powered robotic process automation software designed to handle repetitive and multi-step workflows across enterprise systems. Its platform simulates human actions across digital interfaces, enabling organizations to streamline operations in sectors such as healthcare, finance, and customer service.What differentiates Luminai is its ability to combine healthcare-trained AI models with a configurable workflow engine and human-in-the-loop validation, ensuring accuracy and reliability in highly regulated environments. The platform is built to manage fragmented and unstructured data, transforming it into actionable intelligence that powers end-to-end automation.As healthcare systems worldwide face increasing administrative complexity and operational inefficiencies, solutions like Luminai are emerging as critical infrastructure. The company is already working with major healthcare providers to automate high-volume workflows, improving efficiency and reducing manual burden across operations.The newly raised capital will be used to expand product capabilities, grow engineering and deployment teams, and support rising enterprise demand for scalable AI automation solutions. With total funding now reaching $60 million, Luminai is positioning itself as a key player in the transformation of healthcare operations through AI.

Biotechnology startup Vivatides Therapeutics has secured an oversubscribed $54 million Series A funding round, highlighting strong investor confidence in next-generation RNA therapeutics and delivery technologies.The round was co-led by Qiming Venture Partners along with a leading industry fund, with participation from Highlight Capital, TF Capital, and existing investor Apricot Capital, signaling robust backing from global healthcare-focused investors.Founded in 2025, Vivatides is focused on developing RNA-based therapeutics that target tissues beyond the liver, an area that has historically been difficult due to delivery limitations. Traditional RNA therapies have largely been confined to liver-related applications, leaving a significant gap in treating diseases affecting other organs.The company is building proprietary delivery platforms designed to enable precise targeting of extrahepatic tissues using technologies such as siRNA and antisense oligonucleotides. By improving delivery efficiency, tissue specificity, and safety, Vivatides aims to unlock new treatment possibilities across a wide range of chronic and high-prevalence diseases, including cardiovascular conditions and cancer.The newly raised capital will be used to accelerate the development of its delivery platform, advance multiple pipeline programs toward clinical trials, and expand its global research and development footprint. The company also plans to strengthen its leadership and scientific teams as it scales operations.As RNA therapeutics continue to emerge as a major modality alongside small molecules and biologics, breakthroughs in delivery technologies are becoming critical to unlocking their full potential. Vivatides is positioning itself at the forefront of this shift, targeting one of the most challenging and promising frontiers in modern drug development.

AI-powered compliance startup Haast has raised $12 million in a Series A funding round, underscoring rising investor interest in infrastructure that enables safe and scalable adoption of artificial intelligence across enterprises.The round was led by Peak XV Partners, with participation from DST Global Partners, Airtree, Aura Ventures, and Black Sheep Capital, reflecting strong backing from global investors focused on enterprise AI and regulatory technology.Haast is building an AI-native compliance platform designed to automate regulatory and policy enforcement within enterprise workflows. As organizations increasingly adopt generative AI and scale content production, manual compliance processes are becoming a major bottleneck, slowing down operations and increasing risk exposure.The company addresses this challenge by embedding compliance frameworks directly into everyday tools, allowing businesses to automate high-volume review processes while maintaining strict governance standards. By integrating policy, risk appetite, and approval logic into workflows, Haast enables enterprises to move faster without compromising on compliance.With AI-driven content volumes surging across marketing, product, and go-to-market functions, traditional legal and compliance teams are struggling to keep pace. Haast’s platform aims to eliminate this friction by transforming compliance from a manual checkpoint into an intelligent, automated system that operates at scale.The newly raised capital will be used to scale product development, enhance its AI-driven compliance engine, and expand globally. As regulatory scrutiny around AI intensifies, solutions that enable responsible and compliant deployment are becoming critical to enterprise adoption.With this funding, Haast is positioning itself at the intersection of AI, enterprise software, and regulatory technology, emerging as a key player in the evolving AI infrastructure stack focused on governance, risk, and compliance.